Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | MYLK | Q15746 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988068 | 0.92 | MGLL (0.41) | MGLLFAAHHSPB1CACNA1FCACNA1D | |
| SCHEMBL6199441 | 0.86 | MEN1 (0.44) | MYLKCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6194063 | 0.82 | CACNA1F (0.41) | CACNA1FCACNA1DCACNA1SCACNA1CMEN1 | |
| SCHEMBL6644031 | 0.81 | MYLK (0.39) | MGLLFAAHMYLKPKMCACNA1F | |
| SCHEMBL6195392 | 0.81 | CACNA1F (0.40) | MGLLFAAHCACNA1FCACNA1DCACNA1S | |
| SCHEMBL14760554 | 0.80 | ALDH1A1 (0.43) | MYLKCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6715281 | 0.79 | BCL9 (0.35) | MGLLFAAHTDP2PKMCACNA1F | |
| SCHEMBL6715274 | 0.79 | BCL9 (0.35) | MGLLFAAHTDP2PKMCACNA1F | |
| SCHEMBL6247829 | 0.77 | CACNA1F (0.36) | MGLLFAAHCACNA1FCACNA1DCACNA1S | |
| SCHEMBL6641617 | 0.76 | CACNA1F (0.41) | CACNA1FCACNA1DCACNA1SCACNA1CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473698-B2 | Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof | H. LUNBECK A/S (DK) | 2009-01-06 | — | — | US | disclosed |
| US-20050245743-A1 | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245743-A1 | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | MCHR1, MCHR2, MC1R | MGLL 4499/4885FAAH 682/4885HSPB1 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.